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variables base case were robust in an interval of o 20%. CONCLUSIONS: Viscosup-
plementation is a cost-saving alternative for for the treatment of moderate osteoar-
thritis of knee compared to arthroscopy/lavage in the perspective of Brazilian’s Private 
Sector.
PMS10
ECONOMIC BURDEN OF RHEUMATOID ARTHRITIS IN BRAZILIAN 
PRIVATE HEALTH SYSTEM
Vogel S1, Marante TR2, Monteiro R3
1Axismed Gestão Preventiva de Saúde, Sao Paulo, Sao Paulo, Brazil, 2Wyeth Ind. 
Farmacêutica, São Paulo, Sao Paulo, Brazil, 3Wyeth Ind. Farmacêutica, São Paulo, São Paulo, 
Brazil
OBJECTIVES: Assess RA health care resource utilization in a sample of Brazilian 
private health system beneﬁciaries. METHODS: Three Health Management Organiza-
tion (HMOs) databases were analyzed retrospectively, involving 1,057,033 people, 
corresponding to approximately 3% of total private health system beneﬁciaries in 
Brazil. The analysis was done in 35 months (from January 2004 to November 2007). 
The following health care resources were considered: clinical appointment, hospital-
ization, emergency service, drugs and laboratory exams. All RA patients were com-
pared to non-RA patients in terms of health care resource usage. RESULTS: From 
1,057,033 people analyzed, 4,817 (0.46%) were classiﬁed as having RA, being the 
prevalence rate among women and men 3.5: 1. Those patients concentrated 4.8% 
of the total costs of whole population analyzed. The cost per month/per member 
(cost pm/pm) of RA patients was 6.6 times higher than non-RA population. In addi-
tion, RA patients, compared to non-RA patients, demonstrated 3.4 and 13 times 
higher clinical appointments and hospitalization, respectively. Considering other 
chronic diseases (hypertension, heart failure, asthma, bronchitis and diabetes mellitus 
patients), RA patients demonstrated 1.4 and 3.1 times higher clinical appointments 
and hospitalization, respectively. Comorbiditidy was associated to 33% of RA 
patients, mainly cardiovascular disorders (CVD). CONCLUSIONS: Our results rein-
force the international literature data demonstrating that despite 0.46% prevalence, 
RA has high individual cost (concentrating 4.8% of total costs of whole population 
analyzed) due to multifactor variables, including pharmaceutical assistance and 
comorbidities. Regarding health care resources the study showed that RA patients 
had a higher utilization than non- RA patients, conﬁrming the literature about the 
important cost of the disease in the clinical practice. In addition we suggest an impor-
tant association between RA and comorbidities, especially CVD. In conclusion, RA 
may require speciﬁc strategies by decision makers to optimize its management and 
reduce cost.
MUSCULAR-SKELETAL DISORDERS – Patient-Reported Outcomes Studies
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OBJECTIVES: To assess whether patients with rheumatoid arthritis (RA) who are 
newly initiated on tumor necrosis factor (TNF) antagonists adalimumab, etanercept, 
and inﬂiximab perceive differences in treatment outcomes. METHODS: Study data 
were derived from the 2006 RA Survey (Waves 7 and 8), a nationally (United States) 
representative survey of adults with RA conducted by Consumer Health Sciences 
International. Only patients currently taking TNF antagonists were included. Patients 
with prior self-reported TNF-antagonist use were excluded to avoid potential response 
bias. Responses to 19 questions on various aspects of treatment related to effective-
ness, safety, and patient convenience were collected and converted from an ordered-
response scale to a binary scale (1  favorable response [“strongly agree” or “agree”] 
vs. 0  nonfavorable response [“neither agree nor disagree,” “disagree,” or “strongly 
disagree”]). Chi-square tests identiﬁed signiﬁcant differences between treatments in 
the percentages of patients reporting favorable responses (p  0.05), and odds ratios 
(ORs) were determined using logistic regression, with controls for age and duration 
of RA. RESULTS: The study sample included 303 patients currently taking adalim-
umab (n  83), etanercept (n  133), or inﬂiximab (n  87). The odds of reporting 
favorable outcomes were approximately 2 times greater with adalimumab vs. etaner-
cept for convenience (OR  1.96), no long-term risks (OR  1.93), no short-term 
adverse effects (OR  1.84), symptom relief within 2 weeks (OR  1.98), and increased 
energy within 2 weeks (OR  2.29). The odds of reporting favorable outcomes with 
adalimumab vs. inﬂiximab were greater for convenience (OR  2.78,) and no long-
term risks (OR  2.27). The odds of reporting favorable outcomes with inﬂiximab vs. 
etanercept differed only for symptom relief within 2 weeks (OR  2.27) and increased 
energy within 2 weeks (OR  2.21, p  0.05 for all comparisons). CONCLUSIONS: 
RA patients initiating TNF-antagonist therapy perceived adalimumab to be more 
convenient than etanercept or inﬂiximab. Adalimumab was also perceived to offer 
rapid symptom relief and fewer risks compared with etanercept, and fewer long-term 
risks vs. inﬂiximab.
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OBJECTIVES: To examine the treatment effect of ustekinumab on physical disability 
and QoL in PsA patients using data from a phase II trial. METHODS: Patients with 
active PsA were randomized to ustekinumab 90mg/63mg (n  76) at wks0, 1, 2, and 
3, followed by placebo at wks12 and 16, or placebo at wks0, 1, 2, and 3, followed 
by ustekinumab 63mg at wks12 and 16 (n  70). Physical disability was assessed using 
the disability index from the HAQ (0:no difﬁculty to 3: unable to do) and DLQI 
(range: 0–30) assessed QoL. Clinically meaningful improvement was deﬁned as a 
0.25-point improvement in the disability index, and a 5-point improvement in the 
DLQI. Continuous variables were compared using ANOVA on the van der Waerden 
normal scores. Binary endpoints were compared using Chi-square test. RESULTS: 
Baseline PsA patients had moderate physical disability (mean disability index 1.0) and 
impaired QoL (mean DLQI 11.5). Ustekinumab-treated patients demonstrated signiﬁ-
cant improvement in physical disability as early as 1wk after the ﬁrst dose. After 4 
treatments at wks0, 1, 2 and 3, 60% of patients in the ustekinumab group vs. 28% 
in the placebo group achieved clinically meaningful improvement in disability (HAQ 
responders) at wk12 (p  0.001), and the mean reduction in disability index at wk12 
was 0.31 in the ustekinumab group vs. 0.04 in the placebo group (p  0.001). At 
wk12, 67.0% of HAQ responders maintained response through wk36. 60.3% of 
patients in the ustekinumab group vs. 23.6% in the placebo group achieved a clinically 
meaningful improvement in QoL (DLQI responders) at wk12 (p  0.001). At wk12, 
45.2% of DLQI responders in the ustekinumab group maintained response through 
wk36. Patients in the placebo group who crossed over to ustekinumab at wk12 and 
16 improved in disability and QoL at wk36 similar in magnitude to those initially 
randomized to ustekinumab. CONCLUSIONS: Ustekinumab signiﬁcantly improved 
physical disability and QoL in patients with PsA.
NEUROLOGICAL DISORDERS – Cost Studies
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OBJECTIVES: To determine the budget impact of incorporating levodopa/carbidopa/
entacapone FDC in Distrito Federal’s public reimbursement system for Parkinson 
disease treatment. METHODS: In present analysis, it was considered the quantity 
reimbursed for Distrito Federal in 2007 in Parkinson Disease treatment, based on 
DATASUS (National public health care database). Results were converted in US Dollars 
(R$2.27/USD 1.00). It was considered the medications costs used in Distrito Federal’s 
bidding: USD 0.04/tablet for both combinations of levodopa/carbidopa; USD 0.53/
tablet for both combinations of levodopa/benserazide; USD 0.95/tablet for entacapone. 
Levodopa/benserazide’s presentations have different prices, however to simplify the 
analysis, we took the price of the most used presentation (78% in units) and considered 
it for both. According to DATASUS, considering all levodopas’ combinations reim-
bursed in Distrito Federal in 2007, 62% was levodopa/carbidopa and 38% was 
levodopa/benserazide. The price of all levodopa/carbidopa/entacapone FDC’s were 
ﬁxed in USD 0.97/tablet. A one-way sensitivity analysis was performed. RESULTS: 
In Distrito Federal, the quantities reimbursed in 2007 for entacapone were 43,380 
and for all levodopas’ combinations were 395,510. Considering the prices used in 
Distrito Federal’s bidding, the total of expenses was US$131,311. In this scenario, if 
levodopa/carbidopa/entacapone FDC is used in the place of free dosage combinations, 
then the total of expenses was estimated in US$122,369. The sensitivity analysis on 
cost variables in an interval of o 20% was robust with the base analysis. CONCLU-
SIONS: This budget impact analysis showed a potential economy of US$8942 if 
levodopa/carbidopa/entacapone FDC is incorporated in Distrito Federal’s public reim-
bursement system. Besides, the use of FDC can provide higher adherence of patients 
to the treatment, once it is easier administrating one tablet instead of two or more; 
the patients prefer to take less quantity of tablets; the switches of dosage are easier.
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OBJECTIVES: To determine the budget impact of incorporating levodopa/carbidopa/
entacapone FDC in São Paulo’s public reimbursement system for Parkinson disease 
treatment. METHODS: In present analysis, it was considered the quantity reimbursed 
